$ONC 0.57 Developing

Notable posts

• @wallstengine neutral 27 eng

  BEONE MEDICINES $ONC Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $1.7B (Est. $1.61B) 🟢; +30% YoY 🔹 Adj. EPS: $3.84 (Est. $1.58) 🟢; +71% YoY 🔹 BRUKINSA Revenue: $1.2B; +31% YoY 🔹 Net Income: $237.0M (Est. $161M) 🟢; +151% YoY Raises FY26 Guide: 🔹 Revenue: $6.6B-$6.8B (Est. $6.48B) 🟢 🔹 GAAP Operating Income: $1.0B-$1.1B (Est. $938M) 🟢 🔹 Non-GAAP Operating Income: $1.7B-$1.8B 🔹 GAAP Gross Margin: High-80% range 🔹 GAAP Operating Expenses: $4.8B-$5.0B 🔹 Other Income (Expense): $25M-$50M in expense 🔹 Diluted ADS Outstanding: ~118M Segment Net Revenue: 🔹 BRUKINSA: $1.2B; +31% YoY 🔹 TEVIMBRA: $229M; +18% YoY 🔹 Amgen in-licensed products: $157M; +25% YoY Other Q2 Metrics: 🔹 Gross Margin: 90%; +300 bps YoY 🔹 Free Cash Flow: $435.3M; +98% YoY 🔹 GAAP Operating Income: $325.0M; +270% YoY Comments: 🔸 “Our foundational hematology franchise, led by BRUKINSA, continues to gain momentum as we advance one of the industry’s deepest and most diverse pipelines.”

  view on X →
• @faststocknewss neutral 13 eng

  TRUMP ANNOUNCES NEW DRUG-PRICING AGREEMENTS Trump names BeOne Medicines $ONC and CSL $CSL.AX as the companies involved.

  view on X →